ImmunityBio(IBRX) - 2025 Q1 - Quarterly Results

Financial Results - ImmunityBio, Inc. reported estimated net product revenue and unit sales volume for the three-month period ended March 31, 2025[4]. - The financial results are preliminary estimates and may differ materially from the actual results to be reported in the Quarterly Report on Form 10-Q[5]. - The report does not include comprehensive financial results or position as of March 31, 2025[5]. Company Information - The company is listed on The Nasdaq Global Select Market under the symbol IBRX[2]. - The company is incorporated in Delaware and has an IRS Employer Identification No. 43-1979754[1]. - The company has not indicated if it is an emerging growth company[3]. Report Details - The press release providing the business update was issued on April 15, 2025[4]. - The report was signed by David C. Sachs, Chief Financial Officer, on April 15, 2025[10]. - The report includes an Interactive Data File embedded within the Inline XBRL document[7]. - The information provided is not deemed "filed" under the Securities Exchange Act of 1934[6].